Expertise in
1
conditions

Burkhard C. Schmidt

Munich, BY, DE 
Expertise in
1
conditions
Munich, BY, DE 

Overview

Burkhard Schmidt practices practicing medicine in Munich, Germany.

Schmidt is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Myelodysplastic Syndrome (MDS), Leukemia, Myelofibrosis, and Acute Myeloid Leukemia (AML).

They are actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 2 clinical trials.

Locations

Munich, BY, Germany
Other Locations
Goettingen, NI 37077, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3
Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Enrollment Status: Terminated
Publish Date: December 02, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

21 Total Publications

Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera - German real-world data (PaVe study).
Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera - German real-world data (PaVe study).
Journal: Annals of hematology
Published: October 22, 2025

Frequently Asked Questions about Burkhard C. Schmidt

Is Burkhard C. Schmidt a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Burkhard C. Schmidt is classified as an Advanced expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Burkhard C. Schmidt participate in research or clinical trials?

Yes. Burkhard C. Schmidt has published 21 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Burkhard C. Schmidt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Schmidt's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile